MCM
AXSM icon

MAI Capital Management’s Axsome Therapeutics AXSM Stock Holding History

MAI Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49.2K Sell
291
-1
-0.3% -$173 ﹤0.01% 2230
2025
Q4 		$53.3K Buy
292
+1
+0.3% +$140 ﹤0.01% 1977
2025
Q3 		$35.3K Hold
291
– – ﹤0.01% 2124
2025
Q2 		$30.4K Hold
291
– – ﹤0.01% 2140
2025
Q1 		$33.9K Hold
291
– – ﹤0.01% 1944
2024
Q4 		$24.6K Buy
+291
New +$26.8K ﹤0.01% 2125

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MAI Capital Management's AXSM Position: Q1 2026 in Review

MAI Capital Management reduced its Axsome Therapeutics (AXSM) stake by 0.34% in Q1 2026, selling an estimated $173 and leaving 291 shares worth $49.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2230.

MAI Capital Management first reported a position in AXSM in Q4 2024 and has held it in 6 quarters since. The position peaked at $53.3K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • MAI Capital Management held 291 shares of Axsome Therapeutics worth $49.2K as of Q1 2026.
  • MAI Capital Management sold 1 Axsome Therapeutics share in Q1 2026, an estimated $173.
  • Axsome Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #2230 holding.
  • MAI Capital Management first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • MAI Capital Management's Axsome Therapeutics position peaked at $53.3K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.